Meeting
2019 Genitourinary Cancers Symposium
Sites of metastasis (mets) and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).
Authors
Dylan J Martini
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA
Dylan J Martini , Julie M. Shabto , Yuan Liu , Bradley Curtis Carthon , Alexandra Speak , Elise Hitron , Greta Russler , Sarah Caulfield , Kenneth Ogan , Wayne Harris , Viraj A. Master , Omer Kucuk , Mehmet Asim Bilen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 585)
DOI
10.1200/JCO.2019.37.7_suppl.585
Abstract #
585
Poster Bd #
F2
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Analysis of toxicity and clinical outcomes (CO) in full versus reduced dose cabozantinib (cabo) in metastatic renal cell carcinoma (mRCC) patients (pts).
First Author: Dylan J Martini
Poster
2023 ASCO Annual Meeting
Site of metastasis (SoM) and its impact on clinical outcomes in 8 cancer cohorts.
First Author: Rohini George
Poster
2021 ASCO Annual Meeting
Phase I/II trial of pembrolizumab and cabozantinib in the treatment of metastatic renal cell carcinoma (mRCC).
First Author: Elizabeth R Kessler
Poster
2020 Genitourinary Cancers Symposium
Novel risk scoring system for metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (C).
First Author: Meredith R Kline